US4029767A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions of stable urokinase-heparin complexes and methods for use thereof
Assignee: Choay SA
•
Filing: 1975-11-05
•
Granted: 1977-06-14
•
Expires: 1995-11-05
Abstract
Abstract The present invention relates to pharmaceutical compositions of stable urokinase-heparin complexes, wherein the urokinase is purified, and methods for use thereof.
Inventors
- 👤 Edmond G. Vairel
- 👤 Jean Goulay
- 👤 Jean Choay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 08:07
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6462; C12Y; C12Y304/00; C12Y304/21; C12Y304/21073; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
32 words
Solution for perfusion, containing an effective amount urokinase heparinate in association with an isotonic perfusion solution acceptable by the organism, compatible with urokinase, not precipitating with heparin and free of mineral salts.
Claim 2
Dependent Claim
32 words
Solution for perfusion, containing an effective amount urokinase heparinate in association with an isotonic perfusion solution acceptable by the organism, compatible with urokinase, not precipitating with heparin and free of mineral salts.
Claim 3
Dependent Claim
14 words
Solution according to claim 1, wherein said solution is constituted by isotonic glucose serum.
Claim 4
Dependent Claim
21 words
Solution according to claim 1, wherein its dilution is of the order of 300,000 to 900,000 CTA units of urokinase/250 ml.
Claim 5
Dependent Claim
21 words
Solution according to claim 3, wherein its dilution is of the order of 300,00 to 600,000 CTA units of urokinase/250 ml.
Claim 6
Dependent Claim
31 words
Method of treating patients having thrombolytic or fibrinolytic disorders, comprising the administration by perfusion to said patients of effective doses of a solution based on urokinase heparinate according to claim 1.
Claim 7
Dependent Claim
22 words
Method according to claim 5, comprising administering to said patients doses of 50,000 to 150,000 CTA units of urokinase/hour for 24 hours.
Claim 8
Dependent Claim
22 words
Method according to claim 5, comprising administering to said patients doses of 50,000 to 100,000 CTA units of urokinase/hour for 24 hours.
Claim 9
Dependent Claim
37 words
An composition for preventing formation of thrombi or for causing the lysis of thrombi which comprises a therapeutically effective amount of a stable urokinaseheparin complex wherein the urokinase is purified, in combination with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
37 words
An composition for preventing formation of thrombi or for causing the lysis of thrombi which comprises a therapeutically effective amount of a stable urokinaseheparin complex wherein the urokinase is purified, in combination with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
24 words
The urolinase-heparin complex of claim 8 wherein the heparin is complexed with highly purified urokinase, the complex having retained essentially all its urokinase activity.
Claim 12
Dependent Claim
11 words
The composition of claim 9 wherein the urokinaseheparin complex is apyrogenic.
Claim 13
Dependent Claim
14 words
The composition of claim 9 wherein the urokinase-heparin complex is free of vasopressive substances.
Claim 14
Dependent Claim
13 words
The composition of claim 9 wherein the urokinase-heparin complex is a lyophilized complex.
Claim 15
Dependent Claim
9 words
The composition of claim 9 which is a solution.
Claim 16
Dependent Claim
14 words
The composition of claim 13 in which the solution is a isotonic perfusion solution.
Claim 17
Dependent Claim
18 words
The composition of claim 9 wherein the activity of heparin respective the activity of urokinase is comparatively negligible.
Claim 18
Dependent Claim
34 words
The composition of claim 15 wherein the urokinase-heparin complex has a ratio of heparin to urokinase activity of 100 I.U. per milligram of heparin ot 30,000 to 100,000 C.T.A. units per milligram of urokinase.
Claim 19
Dependent Claim
24 words
The method of treating thrombo-embolic syndromes which comprises treating a patient so afflicted with a therapeutically effective amount of the composition of claim 9.
Claim 20
Dependent Claim
11 words
The method of claim 17 which comprises preventing formation of thrombi.
Claim 21
Dependent Claim
12 words
The method of claim 17 which comprises causing the lysis of thrombi.
Claim 22
Dependent Claim
10 words
The method of claim 17 which comprises treating myocardial infarctus.
References Cited (Backward Citations)
US3726969A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-06-13 | 1980-12-13 | 1981-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-06-13 | 1984-12-13 | 1985-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-06-13 | 1988-12-13 | 1989-06-14 | $7700.00 | Window Closed / Lapsed |